| 2024年中报 | 2023年年报 | 2023年中报 | 2023年一季报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|---|
| 营业收入(元) | ||||||
| 羟苯磺酸钙胶囊(元) | - | - | 31,289,731.59 | - | - | 30,575,535.24 |
| 研发服务收入(元) | - | - | - | 7,940,829.51 | - | 6,297,946.04 |
| 眼用制剂(元) | - | - | 3,641,479.95 | - | - | 3,386,817.74 |
| 吲达帕胺缓释片(元) | - | - | 5,435,776.15 | - | - | 7,036,220.13 |
| 化学药品制造(元) | 34,290,828.90 | 112,271,005.69 | - | - | 112,894,176.99 | - |
| 医药合同外包服务(元) | 12,181,094.68 | 41,462,096.83 | 17,802,173.01 | - | 53,424,526.07 | - |
| 仿制药销售(元) | - | - | - | 13,408,040.31 | - | - |
| 原料药销售(元) | - | - | - | 2,957,966.81 | - | - |
| 羟苯磺酸钙原料药(元) | - | - | 5,586,018.22 | - | - | - |
| 其他(元) | - | - | - | - | - | 3,305,413.67 |
| 其他药品(元) | - | - | 2,085,265.13 | - | - | - |
| 营业成本(元) | ||||||
| 羟苯磺酸钙胶囊(元) | - | - | 7,395,050.75 | - | - | 5,849,506.71 |
| 研发服务收入(元) | - | - | - | - | - | 5,296,456.46 |
| 眼用制剂(元) | - | - | 2,213,082.36 | - | - | 1,735,928.31 |
| 吲达帕胺缓释片(元) | - | - | 1,439,110.23 | - | - | 1,559,799.58 |
| 化学药品制造(元) | 12,186,877.03 | 38,652,393.66 | - | - | 29,673,773.81 | - |
| 医药合同外包服务(元) | 6,668,301.03 | 15,104,010.18 | 8,122,760.01 | - | 14,986,331.93 | - |
| 仿制药销售(元) | - | - | - | - | - | - |
| 原料药销售(元) | - | - | - | - | - | - |
| 羟苯磺酸钙原料药(元) | - | - | 2,981,018.93 | - | - | - |
| 其他(元) | - | - | - | - | - | 2,630,557.37 |
| 其他药品(元) | - | - | 2,584,782.20 | - | - | - |
| 毛利(元) | ||||||
| 羟苯磺酸钙胶囊(元) | - | - | 23,894,680.84 | - | - | 24,726,028.53 |
| 研发服务收入(元) | - | - | - | - | - | 1,001,489.58 |
| 眼用制剂(元) | - | - | 1,428,397.59 | - | - | 1,650,889.43 |
| 吲达帕胺缓释片(元) | - | - | 3,996,665.92 | - | - | 5,476,420.55 |
| 化学药品制造(元) | 22,103,951.87 | 73,618,612.03 | - | - | 83,220,403.18 | - |
| 医药合同外包服务(元) | 5,512,793.65 | 26,358,086.65 | 9,679,413.00 | - | 38,438,194.14 | - |
| 仿制药销售(元) | - | - | - | - | - | - |
| 原料药销售(元) | - | - | - | - | - | - |
| 羟苯磺酸钙原料药(元) | - | - | 2,604,999.29 | - | - | - |
| 其他(元) | - | - | - | - | - | 674,856.30 |
| 其他药品(元) | - | - | -499,517.07 | - | - | - |
| 毛利率(%) | ||||||
| 羟苯磺酸钙胶囊(%) | - | - | 76.37 | - | - | 80.87 |
| 研发服务收入(%) | - | - | - | - | - | 15.90 |
| 眼用制剂(%) | - | - | 39.23 | - | - | 48.74 |
| 吲达帕胺缓释片(%) | - | - | 73.53 | - | - | 77.83 |
| 化学药品制造(%) | 64.46 | 65.57 | - | - | 73.72 | - |
| 医药合同外包服务(%) | 45.26 | 63.57 | 54.37 | - | 71.95 | - |
| 仿制药销售(%) | - | - | - | - | - | - |
| 原料药销售(%) | - | - | - | - | - | - |
| 羟苯磺酸钙原料药(%) | - | - | 46.63 | - | - | - |
| 其他(%) | - | - | - | - | - | 20.42 |
| 其他药品(%) | - | - | -23.95 | - | - | - |
| 收入构成(%) | ||||||
| 羟苯磺酸钙胶囊(%) | - | - | 47.52 | - | - | 60.42 |
| 研发服务收入(%) | - | - | - | 32.67 | - | 12.45 |
| 眼用制剂(%) | - | - | 5.53 | - | - | 6.69 |
| 吲达帕胺缓释片(%) | - | - | 8.26 | - | - | 13.91 |
| 化学药品制造(%) | 73.79 | 73.03 | - | - | 67.88 | - |
| 医药合同外包服务(%) | 26.21 | 26.97 | 27.04 | - | 32.12 | - |
| 仿制药销售(%) | - | - | - | 55.16 | - | - |
| 原料药销售(%) | - | - | - | 12.17 | - | - |
| 羟苯磺酸钙原料药(%) | - | - | 8.48 | - | - | - |
| 其他(%) | - | - | - | - | - | 6.53 |
| 其他药品(%) | - | - | 3.17 | - | - | - |
| 毛利构成(%) | ||||||
| 羟苯磺酸钙胶囊(%) | - | - | 58.13 | - | - | 73.74 |
| 研发服务收入(%) | - | - | - | - | - | 2.99 |
| 眼用制剂(%) | - | - | 3.48 | - | - | 4.92 |
| 吲达帕胺缓释片(%) | - | - | 9.72 | - | - | 16.33 |
| 化学药品制造(%) | 80.04 | 73.64 | - | - | 68.40 | - |
| 医药合同外包服务(%) | 19.96 | 26.36 | 23.55 | - | 31.60 | - |
| 仿制药销售(%) | - | - | - | - | - | - |
| 原料药销售(%) | - | - | - | - | - | - |
| 羟苯磺酸钙原料药(%) | - | - | 6.34 | - | - | - |
| 其他(%) | - | - | - | - | - | 2.01 |
| 其他药品(%) | - | - | -1.22 | - | - | - |